drugset / Trial / NCT02057172

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

NCT02057172

Phase 2 Completed 254 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus (T2DM).

Timeline

Start
2014-01
Primary completion
2014-10
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Efpeglenatide Peptide 0.3 mg Subcutaneous
Subject Efpeglenatide Peptide 1 mg Subcutaneous
Subject Efpeglenatide Peptide 2 mg Subcutaneous
Subject Efpeglenatide Peptide 3 mg Subcutaneous
Subject Efpeglenatide Peptide 4 mg Subcutaneous
Comparator Liraglutide Peptide 1.8 mg